Raymond James Financial Upgrades Avalyn Pharma (NASDAQ:AVLN) to Moderate Buy

Avalyn Pharma (NASDAQ:AVLN) was upgraded by investment analysts at Raymond James Financial to a “moderate buy” rating in a note issued to investors on Friday, Zacks reports.

AVLN has been the subject of several other research reports. Wall Street Zen lowered shares of Avalyn Pharma from a “hold” rating to a “sell” rating in a report on Sunday, September 20th. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research note on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Finally, Morgan Stanley increased their price objective on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $60.00.

Avalyn Pharma Trading Up 2.6%

Shares of AVLN stock opened at $28.13 on Friday. The firm has a market capitalization of $1.25 billion and a PE ratio of -1.23. The company has a 50-day moving average of $33.49. The company has a current ratio of 33.12, a quick ratio of 33.12 and a debt-to-equity ratio of 0.04. Avalyn Pharma has a 1-year low of $24.15 and a 1-year high of $40.17.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. Sell-side analysts forecast that Avalyn Pharma will post -3.81 earnings per share for the current year.

Institutional Investors Weigh In On Avalyn Pharma

Hedge funds have recently added to or reduced their stakes in the business. Montanova Capital LLC acquired a new position in Avalyn Pharma in the second quarter valued at approximately $82,402,000. Braidwell LP acquired a new stake in shares of Avalyn Pharma during the 2nd quarter worth approximately $26,382,000. State Street Corp bought a new stake in shares of Avalyn Pharma in the 2nd quarter valued at $10,501,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma during the 2nd quarter valued at $1,321,000.

About Avalyn Pharma

Avalyn Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious fibrotic lung diseases. The company’s primary focus is pulmonary fibrosis, a group of progressive conditions in which scar tissue builds up in the lungs and impairs breathing.

Avalyn’s lead product candidate is AP01, an inhaled formulation of pirfenidone being developed for the treatment of idiopathic pulmonary fibrosis and other forms of pulmonary fibrosis. By delivering therapy directly to the lungs, Avalyn aims to provide a treatment option that may improve local drug exposure while potentially reducing some of the tolerability challenges associated with oral antifibrotic therapies.

The company’s development programs are centered on advancing inhaled medicines through clinical testing and, if successful, regulatory review.